The technologies that enable immunotherapies are playing an increasingly critical role in determining how the immune system of a patient will respond to a specific tumor. As immunotherapies become the standard of care for cancer treatments, previous researchuse only technologies like Next Generation Sequencing, RNASeq, MultiParameter Flow Cytometry, and Imaging Mass Cytometry are now being used in clinical setting. The effectiveness of these tools is vital. In this documentary, Biocompare taps the expertise of key opinion leaders, including Craig Monell, VP of Business Operations, BioLegend, to explore how immunotherapies and their supporting technologies are transforming patient care.